Expression of steap1 and steap1b in prostate cell lines, and the putative regulation of steap1 by post-transcriptional and post-translational mechanisms

Genes and Cancer

Volumn 5, Issue 3-4, 2014, Pages 142-151

  Gomes, Inês M ^a   Santos, Cecília R ^a   Maia, Cláudio J ^a  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Post transcriptional; Post translational; Prostate cancer; STEAP1; STEAP1B

Indexed keywords

N ACETYLGLUCOSAMINE; PEPTIDES AND PROTEINS; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1 B; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; GLYCATION; GLYCOSYLATION; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84938556050     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U, da Silva-Buttkus P, Neff F, Unland R, Muller-Tidow C, Zobywalski C, Lohrig K, Lewandrowski U, Sickmann A, Prazeres da Costa O, Gorlach A, et al. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res. 2012; 10(1):52-65.
2. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC and Afar DEH. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A. 1999; 96(25):14523-14528.
3. Maia CJB, Socorro S, Schmitt F and Santos CR. STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland. Endocrine. 2008; 34(1-3):108-116.
4. Yang D, Holt GE, Velders MP, Kwon ED and Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res. 2001; 61(15):5857-5860.
5. Gomes IM, Santos CR, Socorro S and Maia CJ. Six transmembrane epithelial antigen of the prostate 1 is down-regulated by sex hormones in prostate cells. The Prostate. 2012; 73(6):605-613.
6. Challita-Eid PM, Morrison K, Etessami S, An Z, Morrison KJ, Perez-Villar JJ, Raitano AB, Jia X-C, Gudas JM, Kanner SB and Jakobovits A. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res. 2007; 67(12):5798-5805.
7. Alves PMS, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross D-A, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA and Kosmatopoulos K. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother. 2006; 55(12):1515-1523.
8. Azumi M, Kobayashi H, Aoki N, Sato K, Kimura S, Kakizaki H and Tateno M. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer. J Urol. 2010; 183(5):2036-2044.
9. Garcia-Hernandez MDLL, Gray A, Hubby B and Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 2007; 67(3):1344-1351.
10. Grunewald T, Ranft A, Esposito I, da Silva-Buttkus P, Aichler M, Baumhoer D, Schaefer K, Ottaviano L, Poremba C and Jundt G. High STEAP1 expression is associated with improved outcome of Ewing's sarcoma patients. Ann Oncol. 2012; 23(8):2185-2190.
11. Valenti MT, Dalle Carbonare L, Donatelli L, Bertoldo F, Giovanazzi B, Caliari F and Lo Cascio V. STEAP mRNA detection in serum of patients with solid tumours. Cancer Lett. 2009; 273(1):122-126.
12. Kirkpatrick DS, Denison C and Gygi SP. Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nature cell biology. 2005; 7(8):750-757.
13. Hershko A and Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998; 67:425-479.
14. King RW, Deshaies RJ, Peters JM and Kirschner MW. How proteolysis drives the cell cycle. Science. 1996; 274(5293):1652-1659.
15. Hao S and Baltimore D. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nature immunology. 2009; 10(3):281-288.
16. Friedel CC, Dolken L, Ruzsics Z, Koszinowski UH and Zimmer R. Conserved principles of mammalian transcriptional regulation revealed by RNA half-life. Nucleic Acids Res. 2009; 37(17):e115.
17. Hollams EM, Giles KM, Thomson AM and Leedman PJ. mRNA stability and the control of gene expression: implications for human disease. Neurochemical research. 2002; 27(10):957-980.
18. Aghib DF, Bishop JM, Ottolenghi S, Guerrasio A, Serra A and Saglio G. A3' truncation of MYC caused by chromosomal translocation in a human T-cell leukemia increases mRNA stability. Oncogene. 1990; 5(5):707-711.
19. Hollis GF, Gazdar AF, Bertness V and Kirsch IR. Complex translocation disrupts c-myc regulation in a human plasma cell myeloma. Mol Cell Biol. 1988; 8(1):124-129.
20. Jones TR and Cole MD. Rapid cytoplasmic turnover of c-myc mRNA: requirement of the 3' untranslated sequences. Mol Cell Biol. 1987; 7(12):4513-4521.
21. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J and Clark AR. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol. 2000; 20(12):4265-4274.
22. Ross HJ, Sato N, Ueyama Y and Koeffler HP. Cytokine messenger RNA stability is enhanced in tumor cells. Blood. 1991; 77(8):1787-1795.
23. Schuler GD and Cole MD. GM-CSF and oncogene mRNA stabilities are independently regulated in trans in a mouse monocytic tumor. Cell. 1988; 55(6):1115-1122.
24. Seet BT, Dikic I, Zhou MM and Pawson T. Reading protein modifications with interaction domains. Nat Rev Mol Cell Bio. 2006; 7(7):473-483.
25. Yang XJ. Multisite protein modification and intramolecular signaling. Oncogene. 2005; 24(10):1653-1662.
26. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45.
27. Gomes IM, Santos CR, Socorro S and Maia CJ. Six transmembrane epithelial antigen of the prostate 1 is down-regulated by sex hormones in prostate cells. Prostate. 2012.
28. Johansen MB, Kiemer L and Brunak S. Analysis and prediction of mammalian protein glycation. Glycobiology. 2006; 16(9):844-853.
29. Blom N, Gammeltoft S and Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol. 1999; 294(5):1351-1362.
30. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S and Brunak S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics. 2004; 4(6):1633-1649.
31. Gupta R and Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing. 2002:310-322.
32. Schwarz F and Aebi M. Mechanisms and principles of N-linked protein glycosylation. Current opinion in structural biology. 2011; 21(5):576-582.
33. Wang Z, Pandey A and Hart GW. Dynamic interplay between O-linked N-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. Molecular & Cellular Proteomics. 2007; 6(8):1365-1379.
34. Wang Z, Gucek M and Hart GW. Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proceedings of the National Academy of Sciences. 2008; 105(37):13793-13798.
35. Grunewald TG, Bach H, Cossarizza A and Matsumoto I. The STEAP protein family: versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions. Biol Cell. 2012; 104(11):641-657.
36. Ohgami RS, Campagna DR, McDonald A and Fleming MD. The Steap proteins are metalloreductases. Blood. 2006; 108(4):1388-1394.
37. Finegold AA, Shatwell KP, Segal AW, Klausner RD and Dancis A. Intramembrane bis-heme motif for transmembrane electron transport conserved in a yeast iron reductase and the human NADPH oxidase. J Biol Chem. 1996; 271(49):31021-31024.
38. Ohgami RS, Campagna DR, Greer EL, Antiochos B, Mcdonald A, Chen J, Sharp JJ, Fujiwara Y, Barker JE and Fleming MD. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet. 2005; 37(11):1264-1269.
39. Sanchez-Pulido L, Rojas AM, Valencia A, Martinez-A C and Andrade Ma. ACRATA: a novel electron transfer domain associated to apoptosis and cancer. BMC Cancer. 2004; 4:98.
40. Guhaniyogi J and Brewer G. Regulation of mRNA stability in mammalian cells. Gene. 2001; 265(1-2):11-23.
41. Ross J. mRNA stability in mammalian cells. Microbiological reviews. 1995; 59(3):423-450.
42. Wagner A. Energy constraints on the evolution of gene expression. Mol Biol Evol. 2005; 22(6):1365-1374.
43. Yeap BB, Krueger RG and Leedman PJ. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology. 1999; 140(7):3282-3291.
44. Russell JE, Morales J and Liebhaber SA. The role of mRNA stability in the control of globin gene expression. Prog Nucleic Acid Re. 1997; 57:249-287.
45. Hanson SR, Culyba EK, Hsu TL, Wong CH, Kelly JW and Powers ET. The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proc Natl Acad Sci U S A. 2009; 106(9):3131-3136.
46. Shental-Bechor D and Levy Y. Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc Natl Acad Sci U S A. 2008; 105(24):8256-8261.
47. Ling X, Sakashita N, Takeya M, Nagai R, Horiuchi S and Takahashi K. Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. Lab Invest. 1998; 78(12):1591-1606.
48. Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS and Cho JW. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nature cell biology. 2006; 8(10):1074-1083.
49. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K and Reginato MJ. Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 2012; 287(14):11070-11081.
50. Chu C-S, Lo P-W, Yeh Y-H, Hsu P-H, Peng S-H, Teng Y-C, Kang M-L, Wong C-H and Juan L-J. O-GlcNAcylation regulates EZH2 protein stability and function. Proceedings of the National Academy of Sciences. 2014; 111(4):1355-1360.
51. Yoon SJ, Park SY, Pang PC, Gallagher J, Gottesman JE, Dell A, Kim JH and Hakomori SI. N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. Int J Oncol. 2010; 36(1):193-203.
52. Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, Saito S, Arai Y, Sadilek M, Murayama K, Dell A, Nishimura S and Hakomori SI. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer. 2008; 122(1):39-49.
53. Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O and Nakayama J. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis. 2014; 17(1):18-22.